Company intelligence / Profile preview
iProgen Biotech
Burnaby, British Columbia, Canadaiprogen.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
iProgen is developing novel antibody drug conjugates with enhanced delivery capabilities. Their technology is being applied to develop treatments for various cancers, including breast cancers expressing low levels of HER2.
- Therapeutic areas
- OncologyMetabolic Disorders
- Modalities
- Antibody Drug Conjugates (ADCs)Antibody-PROTAC technologyAntibody Oligo Conjugates
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
CelltrionBiorchestraAbTisPharmaPlanter TechnologiesShanxi Biological Research InstituteAsan Medical CenterUniversity of British Columbia
Beyond the preview
Go deeper on iProgen Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iProgen Biotech.